Specialty Therapeutic Areas
While Teva focuses on developing, personalizing and making treatments accessible for patients across a wide range of therapeutic areas, we have several key areas of focus where our specialty research and development concentrates its efforts. There are treatments for respiratory, pain, migraine and headache, movement and neurodegenerative disorders, and oncology.
Today, 300 million people globally suffer from asthma and chronic lung diseases, suffering attacks of breathlessness and wheezing. Teva is proud to be the second largest global supplier of medicines on the World Health Organization’s (WHO) Essential Medicines List for respiratory conditions. While these diseases are often chronic, the greatest assistance for those living with these conditions is to provide a treatment which can be carried with them and can be administered as efficiently as possible. Accordingly, key to our work developing asthma treatments is improving the efficiency of inhalers for both maintenance and rescue therapies. Our innovative and growing portfolio of digitally integrated combination treatment options has the potential to change the future of care for the respiratory community.
About a billion people around the world are affected by migraines. Many suffer from severe headaches, and others endure debilitating pain, blurred vision and other side-effects, some for as many as 15 days a month or more. Teva has been providing treatments for diseases of the central nervous system for over thirty years. We are working to bring innovative treatments to those suffering from migraine and headache, as well as bringing greater awareness of the impact these conditions can have on peoples’ lives. We also believe there is significant unmet need in chronic pain associated with osteoarthritis, and that new medicines are needed for appropriate patients.
There can be many challenges - physically, financially, and emotionally - faced every day by people living with diseases of the central nervous system and their families. Neurodegenerative conditions and movement disorders such as multiple sclerosis (MS), Parkinson’s Disease (PD), Huntington’s Disease (HD) and Tardive Dyskinesia (TD) affect every aspect of life, with even the most mundane tasks requiring great courage and effort. It is expected that by 2030, we will see a rise of between 30-50% in the incidence of such diseases, with an associated need for increased treatment and care. Teva provides a number of products to treat patients with neurological and neurodegenerative disorders – with a focus on helping patients manage their condition.
When a patient is told they have cancer, their world – and the worlds of their families and loved ones – is turned upside down. within addition to coping with the illness itself, the side-effects of the prescribed treatment can also be harrowing and difficult. Yet, thankfully, there have been tremendous advancements in care in recent years. Teva is proud to be making a profound difference in the lives of people with cancer, as one of the top 5 global suppliers of oncology treatments on the WHO Essential Medicines List.
In addition to a broad portfolio of generic medicines, Teva offers a variety of specialty therapies including treatment for chronic forms of leukaemia and types of non-Hodgkin’s lymphoma, among other types of cancer. Teva is also committed to developing and marketing biosimilars, with the potential to create lower healthcare costs. This focus is consistent with Teva’s mission of making accessible medications to help improve the lives of patients.